Rocket Pharma Posts Interim Data From Immunodeficiency Disorder Gene Therapy Trial

  • Rocket Pharmaceuticals Inc RCKT has announced interim data updates from seven patients from the RP-L201 Phase 1/2 trial for Leukocyte Adhesion Deficiency-I (LAD-I).
  • Data were shared at the Annual Congress of the European Society of Gene & Cell Therapy (ESGCT). RP-L201 is Rocket's ex-vivo lentiviral gene therapy candidate.
  • The interim data demonstrated preliminary efficacy in all seven patients with durable neutrophil CD18 expression that exceeded the 4-10% threshold.
  • Peripheral blood vector copy number (VCN) levels have been stable and in the 0.5 – 2.5 copy per genome range. 
  • No patients have had LAD-I-related infections requiring hospitalization after hematopoietic reconstitution post-RP-L201.
  • The safety profile of RP-L201 appears favorable, with all infusions well tolerated and no drug product-related serious adverse events.
  • Severe LAD-I is a rare, autosomal recessive pediatric disease caused by mutations in the ITGB2 gene encoding the beta-2 integrin component CD18. 
  • CD18 is a key protein that facilitates leukocyte adhesion and extravasation from blood vessels to combat infections. 
  • Read Next: FDA Lifts Clinical Hold On Rocket Pharma's X-Linked Inherited Disorder Trial.
  • Price Action: RCKT shares traded higher 3.06% higher at $29 premarket on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsgene therapyPhase 1 TrialPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!